G-csf and gm-csf in neutropenia
HM Mehta, M Malandra, SJ Corey - The Journal of Immunology, 2015 - journals.aai.org
Abstract G-CSF and GM-CSF are used widely to promote the production of granulocytes or
APCs. The US Food and Drug Administration approved G-CSF (filgrastim) for the treatment …
APCs. The US Food and Drug Administration approved G-CSF (filgrastim) for the treatment …
Pulmonary aspergillosis: a clinical review
M Kousha, R Tadi, AO Soubani - European Respiratory Review, 2011 - Eur Respiratory Soc
Aspergillus is a mould which may lead to a variety of infectious, allergic diseases depending
on the host9s immune status or pulmonary structure. Invasive pulmonary aspergillosis …
on the host9s immune status or pulmonary structure. Invasive pulmonary aspergillosis …
Green‐synthesized silver nanoparticles induced apoptotic cell death in MCF‐7 breast cancer cells by generating reactive oxygen species and activating caspase 3 …
Silver nanoparticles are among the most significant diagnostic and therapeutic agents in the
field of nanomedicines. In the current study, the green chemistry approach was made to …
field of nanomedicines. In the current study, the green chemistry approach was made to …
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the …
M Hallek, BD Cheson, D Catovsky… - Blood, The Journal …, 2008 - ashpublications.org
Standardized criteria for diagnosis and response assessment are needed to interpret and
compare clinical trials and for approval of new therapeutic agents by regulatory agencies …
compare clinical trials and for approval of new therapeutic agents by regulatory agencies …
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non–small-cell lung cancer
GV Scagliotti, P Parikh, J Von Pawel… - Journal of clinical …, 2008 - ascopubs.org
Purpose Cisplatin plus gemcitabine is a standard regimen for first-line treatment of
advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus …
advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus …
Practice guidelines for the diagnosis and management of skin and soft-tissue infections
DL Stevens, AL Bisno, HF Chambers… - Clinical Infectious …, 2005 - academic.oup.com
Soft-tissue infections are common, generally of mild to modest severity, and are easily
treated with a variety of agents. An etiologic diagnosis of simple cellulitis is frequently difficult …
treated with a variety of agents. An etiologic diagnosis of simple cellulitis is frequently difficult …
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult …
MS Aapro, J Bohlius, DA Cameron, L Dal Lago… - European journal of …, 2011 - Elsevier
Chemotherapy-induced neutropaenia is a major risk factor for infection-related morbidity
and mortality and also a significant dose-limiting toxicity in cancer treatment. Patients …
and mortality and also a significant dose-limiting toxicity in cancer treatment. Patients …
Chemotherapy‐induced neutropenia: risks, consequences, and new directions for its management
J Crawford, DC Dale, GH Lyman - Cancer, 2004 - Wiley Online Library
Cytotoxic chemotherapy suppresses the hematopoietic system, impairing host protective
mechanisms and limiting the doses of chemotherapy that can be tolerated. Neutropenia, the …
mechanisms and limiting the doses of chemotherapy that can be tolerated. Neutropenia, the …
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel …
JD Patel, MA Socinski, EB Garon… - Journal of Clinical …, 2013 - ascopubs.org
Purpose PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With
Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of …
Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of …
On the origin of myeloid-derived suppressor cells
CR Millrud, C Bergenfelz, K Leandersson - Oncotarget, 2016 - pmc.ncbi.nlm.nih.gov
Myeloid-derived suppressor cells (MDSCs) have a strong immunosuppressive character that
allows them to regulate immune responses and hinder overt inflammatory responses. In …
allows them to regulate immune responses and hinder overt inflammatory responses. In …